
GRI Stock Forecast & Price Target
GRI Analyst Ratings
Bulls say
GRI Bio Inc is focused on developing innovative therapies for serious immune-related diseases, with promising results from their candidate GRI-0124 in murine models, showing improved overall survival and significant control over lupus nephritis, which may enhance prospects for Phase 3 clinical development. The company's strategic patient population identification could strengthen clinical outcomes and regulatory submissions, increasing the likelihood of successful trial results. Furthermore, the current valuation appears attractive based on a net present value analysis, indicating considerable upside potential as the company continues to progress with its promising therapeutic candidates in the fields of autoimmune disorders and cancer treatment.
Bears say
GRI Bio Inc. faces a negative outlook due to several fundamental financial challenges, including depressed forward multiples attributed to market volatility and uncertainty regarding the efficacy of its clinical candidates—particularly in relation to the functioning of dNKT cells in systemic lupus erythematosus (SLE) patients. The company's net loss of $2.1 million per share indicates financial strain, which could be exacerbated by the need for additional funding to support its multiple development programs and potential regulatory hurdles that may delay product advancement. Furthermore, concerns regarding failed clinical trials, the risk of dilutive capital raises, and the overall lack of commercial success present significant obstacles that may affect GRI Bio’s future viability in the biotech sector.
This aggregate rating is based on analysts' research of GRI Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
GRI Analyst Forecast & Price Prediction
Start investing in GRI
Order type
Buy in
Order amount
Est. shares
0 shares